Effects of Flumazenil on Recovery After Total Intravenous Anesthesia With Remimazolam

• Status: Recruiting
• Trial end date: 2024-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Remimazolam is a medication that has the advantage of a short half-life and reversibility with flumazenil. In clinical situations, the use of flumazenil for the reversal of sedation is common, but there is no precise indication for its administration. In this study, we aim to investigate the necessity of routine flumazenil use after administering remimazolam for intravenous anesthesia.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pusan National University Yangsan Hospital
• Treatments: Flumazenil

Criteria

Inclusion Criteria:

• Patients over 65 years old scheduled for hip joint surgery

Exclusion Criteria:

• Patients with impaired consciousness or delirium before surgery

• Patients who are hemodynamically unstable before surgery

• Patients with a history of neurological or neuromuscular disorders or use of medications that affect neurological or neuromuscular function

• Patients who have taken sedatives (anti-anxiety medications, antipsychotics, antidepressants, sleep aids) within the past 24 hours

• Patients with known allergy to benzodiazepine, flumazenil

• Patients with galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption

• Patients with hypersensitivity to Dextran40

• Patients who have been taking benzodiazepine for long term

• Patients with end stage renal disease requiring hemodialysis

• Patients with history of acute angle glaucoma

• Patients with alcohol or substance dependence

• ASA classification 4 or 5